Managing Director & Partner
Johanna Benesty is a core member of Boston Consulting Group’s Health Care and People & Organization and Social Impact practices.
Since joining BCG in 2007, Johanna has worked with leading health care companies on a wide range of strategic and operational issues, such as defining the go-to-market models for specific vaccines, developing strategies for generics, and defining generic-drug portfolios for emerging markets. She has also helped health care clients plan and execute a number of large-scale transformation initiatives.
In addition, Johanna has extensive experience partnering with social impact organizations dedicated to improving public health. Her work has included providing input on the World Health Organization’s HIV drug-resistance surveillance strategy; supporting the Global Fund to fight AIDS, Tuberculosis, and Malaria in developing partnerships with technical agencies; and assisting the WHO, United Nations, and Partnership for Maternal and Child Health in writing their common action plan.
Prior to joining BCG, Johanna was an intern in the strategy departments of Disneyland Resort Paris, Star Alliance in Frankfurt, and L.E.K. in Paris.
COVID-19 offered valuable lessons in combating epidemic-level disease. Four measures can help institutionalize what we’ve learned.
Companies can take four steps to address the inequitable health outcomes that marginalized and underserved communities experience in the US.
To advance from promise to value, biopharma companies need to articulate and execute a bold vision for analytics as a fully scaled, continuously applied internal capability.
COVID-19 will likely become endemic. If so, a global surveillance, treatment and vaccination infrastructure for monitoring and responding to outbreaks must be developed now.
Protecting the health-vulnerable population first can shave months off a country’s reopening.
What has worked, what can be improved, and what needs to be reimagined so that we are better prepared for the next pandemic and better able to improve health in the world’s poorest nations?
BCG Managing Director & Partner Johanna Benesty looks at barriers to "equitable access"—making sure COVID-19 therapeutics are available to all—and shares a creative approach to vaccine research and development.
Governments cannot let the most vulnerable be the least protected again. Countries, regions, and states can still get the rollout right through science, hard work, and vigilance.
An advanced algorithm helps doctors identify patients at risk of developing a serious kidney complication, enabling hospitals to lower treatment costs and save lives.